Acrivon Therapeutics (ACRV) Cash & Equivalents (2021 - 2026)

Acrivon Therapeutics (ACRV) has reported Cash & Equivalents for 6 consecutive years, with $34.1 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash & Equivalents fell 13.0% year-over-year to $34.1 million; the TTM figure through Mar 2026 stood at $34.1 million (down 13.0% YoY), while the FY2025 annual figure was $41.5 million, up 4.22% from the prior year.
• Cash & Equivalents slipped to $34.1 million in Q1 2026 per ACRV's latest filing, from $41.5 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $90.8 million in Q1 2022 and bottomed at $24.6 million in Q1 2024.
• Historically, Cash & Equivalents has averaged $42.0 million across 5 years, with a median of $38.1 million in 2023.
• On a YoY basis, Cash & Equivalents climbed as much as 787.66% in 2022 and fell as far as 70.36% in 2022.
• Acrivon Therapeutics' Cash & Equivalents stood at $29.5 million in 2022, then rose by 22.01% to $36.0 million in 2023, then gained by 10.56% to $39.8 million in 2024, then gained by 4.22% to $41.5 million in 2025, then dropped by 17.92% to $34.1 million in 2026.
• Business Quant data shows ACRV's Cash & Equivalents at $34.1 million in Q1 2026, $41.5 million in Q4 2025, and $35.4 million in Q3 2025.